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Wada Test Reliability (Response to Haber et al.)
Tobias Loddenkemper MD, Harold H. Morris MD, Tara T. Lineweaver PhD, Christoph
Kellinghaus MD
To the Editors:
We thank Dr. Haber and colleagues for their kind letter, and we are grateful for their comments.
We also thank the editors for an opportunity to respond.
We agree with Dr. Haber that our results alone cannot support a strong conclusion about
the statistical reliability of the Wada test. Our study was not specifically designed to test IAT
reliability. Because of the retrospective study design, the two tests that were being compared on
each patient differed in a number of respects (Loddenkemper et al., 2007b). In fact, as Haber and
colleagues point out, failure of the first test was the most frequent trigger for the second test in
our study. Even prospective studies may encounter similar difficulties due to ethical and
procedural difficulties in the future.
Our conclusions in the last paragraph of our paper were drawn not only from our own
results, but also from a review of the literature. This review included the experience from the
South Florida Comprehensive Epilepsy Center including the authors of the letter to which we are
responding (Benbadis and Heriaud, 2005). Interestingly, their abstract demonstrated the largest
percentage change in repeated IAT memory test results without “confounding factors” reported
to date (89%). Benbadis and Heriaud found “reversed memory test scores without obvious
cause” in 9 cases. “Of 9 ‘reversed’ Wadas, 8 repeat tests were no longer ‘reversed,’” and this was
interpreted as “significant test-retest variability for memory results.” We believe that their
findings (which take into account confounding factors), together with our own (which show that
most repeat IAT tests involve confounding factors), call into question the reliability of the
memory part of the IAT.
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Haber et al. mention invalidity of the IAT as possibly limiting our ability to draw
conclusions about its reliability. We would argue that invalidity of the IAT actually limits its
reliability. Problems with the validity of the memory IAT have been discussed in detail in our
manuscript. No gold standard for memory assessment–besides resection and subsequent
amnesia–exists. Neuropsychological testing, fMRI, and IAT may all assess different aspects of
memory and may therefore be hard to compare. “Validity” of the test may therefore be
influenced by the observer. How to judge a trial as valid is unclear, particularly since, as Haber et
al. state, “memory testing requires the sustained attention and participation of the patient…, and
reactions to the various medications used in the Wada test can vary unpredictably.” With so
much variability, it is difficult to determine whether a trial is valid. As a result, we would argue
that clinicians should seriously question whether the result of an IAT memory test would be the
same or different if repeated later.
We agree with Haber et al. that Brevital may be an alternative to amobarbital. However,
Brevital injections bear the increased risk of more frequent seizures (Loddenkemper et al.,
2007a). Additionally, retesting with Brevital during a single catheterization will also require
more time and more frequent injections. This prolonged interval and additional manipulations
with an indwelling intraarterial catheter in place may also cause additional complications
(Loddenkemper et al., 2002).
We appreciate Dr. Haber's comments about our paper and the opportunity to respond to
them. Issues surrounding the IAT are important not only to us as clinicians, but also to our
patients. We encourage further discussion of this test and future research addressing these
questions.
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